MaxCyte announced that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to begin a clinical study in the United States with its first wholly-owned chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11.
{iframe}https://www.maxcyte.com/maxcyte-receives-us-fda-investigational-new-drug-clearance-for-first-clinical-program/?platform=hootsuite{/iframe}